D-0611-2026 Class II Ongoing

Recalled by Ajanta Pharma USA Inc — Bridgewater, NJ

FDA drug recall D-0611-2026 was initiated by Ajanta Pharma USA Inc on May 28, 2026 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: 3648 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 1, 2026
Initiation Date
May 28, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3648 bottles

Product description

Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04.

Reason for recall

CGMP Deviations

Distribution pattern

U.S. Nationwide

Code information

Lot # PA02216; Exp. 12/2029

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0611-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0611-2026. Report a data issue: hello@regdatalab.com.